Key Points
- COO Julie Rubinstein sold 19,037 shares on April 27 for $270,896.51 under a pre-arranged Rule 10b5-1 plan and has sold roughly 233,399 shares across April, reducing her position by 4.8% to 377,802 shares.
- Adaptive's stock opened at $13.53 (down ~3.6%), and while the company beat the quarter—EPS of -$0.09 vs. -$0.19 expected and revenue of $71.68M (up 51% YoY)—it remains unprofitable; analysts give a consensus rating of "Moderate Buy" with an average target of $18.25.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) COO Julie Rubinstein sold 19,037 shares of the company's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $14.23, for a total value of $270,896.51. Following the completion of the sale, the chief operating officer owned 377,802 shares of the company's stock, valued at $5,376,122.46. This represents a 4.80% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Julie Rubinstein also recently made the following trade(s):
- On Wednesday, April 22nd, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.13, for a total value of $269,317.80.
- On Friday, April 24th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.02, for a total value of $267,221.20.
- On Tuesday, April 21st, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.66, for a total value of $453,595.06.
- On Monday, April 20th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.55, for a total value of $277,323.00.
- On Thursday, April 16th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.18, for a total value of $270,270.80.
- On Monday, April 13th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.15, for a total value of $250,639.00.
- On Friday, April 10th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $12.77, for a total value of $243,396.20.
- On Tuesday, April 7th, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $13.56, for a total value of $258,453.60.
- On Wednesday, April 8th, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.83, for a total value of $458,855.03.
- On Wednesday, April 1st, Julie Rubinstein sold 19,060 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $14.45, for a total value of $275,417.00.
Adaptive Biotechnologies Trading Down 3.6%
NASDAQ:ADPT opened at $13.53 on Thursday. Adaptive Biotechnologies Corporation has a 1 year low of $7.16 and a 1 year high of $20.76. The stock has a market cap of $2.08 billion, a price-to-earnings ratio of -33.82 and a beta of 2.29. The stock has a 50-day moving average price of $14.39 and a two-hundred day moving average price of $15.95.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million during the quarter, compared to analysts' expectations of $59.38 million. During the same period in the previous year, the firm earned ($0.23) earnings per share. The company's revenue was up 51.0% on a year-over-year basis. Sell-side analysts forecast that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current year.
Analysts Set New Price Targets
A number of research analysts have issued reports on ADPT shares. BTIG Research boosted their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, February 6th. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research note on Friday, February 6th. Guggenheim boosted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Monday, January 26th. JPMorgan Chase & Co. boosted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Finally, Wall Street Zen cut Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Adaptive Biotechnologies has an average rating of "Moderate Buy" and a consensus price target of $18.25.
Read Our Latest Stock Report on ADPT
Institutional Trading of Adaptive Biotechnologies
Institutional investors have recently modified their holdings of the company. Caitong International Asset Management Co. Ltd bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $28,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Adaptive Biotechnologies by 197.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock valued at $38,000 after purchasing an additional 1,565 shares in the last quarter. Assetmark Inc. lifted its holdings in shares of Adaptive Biotechnologies by 867.9% in the fourth quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after purchasing an additional 2,708 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $51,000. Finally, Strive Financial Group LLC bought a new stake in shares of Adaptive Biotechnologies in the fourth quarter valued at about $52,000. 99.17% of the stock is currently owned by institutional investors.
About Adaptive Biotechnologies
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
